BP’s Moderna MRNA Stock Holding History

BP’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,269	Closed	-$1.71M	–	340
2021 Q2	$1.71M	Sell	7,269 -1,740	-19%	-$311K	0.07%	160
2021 Q1	$1.18M	Sell	9,009 -1,938	-18%	-$281K	0.04%	261
2020 Q4	$1.14M	Buy	+10,947	New	+$1.11M	0.03%	295

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

BP's MRNA Position: Q3 2021 in Review

BP sold out of Moderna (MRNA) in Q3 2021, closing a stake of 7,269 shares — an estimated $1.71M sold.

BP first reported a position in MRNA in Q4 2020 and held it in 3 quarters. The position peaked at $1.71M in Q2 2021. 1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

BP reported no remaining Moderna position as of Q3 2021 after selling out during the quarter.
BP sold 7,269 Moderna shares in Q3 2021, an estimated $1.71M.
BP first reported a position in Moderna in Q4 2020 and held it in 3 quarters.
BP's Moderna position peaked at $1.71M in Q2 2021.
1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.